Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs First Trust Cloud Computing ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while First Trust Cloud Computing ETF trades at $138.17. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SKYY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $155.17 |
52-Week Low | $278.09 | $104.16 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SKYY (First Trust Cloud Computing ETF) trades at $139.77, down 1.47% today, with strong technical momentum indicated by bullish moving averages. The ETF provides diversified exposure to cloud computing companies amid growing enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs and cloud computing sector strength.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include sector concentration and technology volatility. Analyst coverage suggests the ETF offers strategic exposure to a high-growth technology segment with institutional-grade market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
